Adiposogenital dystrophy medical therapy

Adiposogenital dystrophy Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Adiposogenital dystrophy from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Head X Ray
CT
MRI
Vision Test
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Adiposogenital dystrophy medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Adiposogenital dystrophy medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Adiposogenital dystrophy medical therapy
CDC on Adiposogenital dystrophy medical therapy
Adiposogenital dystrophy medical therapy in the news
Blogs on Adiposogenital dystrophy medical therapy
Directions to Hospitals Treating Adiposogenital dystrophy
Risk calculators and risk factors for Adiposogenital dystrophy medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Ogechukwu Hannah Nnabude, MD

Overview

The genital signs, low B.M.R., and obesity in many cases disappear during or after puberty without any treatment due to genital development and with the correction of B.M.R.. The genital under-development seen in adiposogenital dystrophy responds to injections of pregnancy urine extract follutein (Squibb).

Medical therapy

The genital under-development seen in adiposogenital dystrophy responds to injections of pregnancy urine extract follutein (Squibb)